Matina Brothers

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Monday, January 30, 2023
Transfer, Biomedical Advanced Research and Development Authority, RNA, Necessity and sufficiency, Disease, Lipofectamine, Food, Phase II, Safety, Oligonucleotide, Mycosis, Attention, HeLa, Mucormycosis, NYSE, BioNTech, Gene expression, Evaluation, Mucor, Sirna, Vaccine, ASO, Cryptococcosis, Aspergillosis, Survival, Therapy, Conference, Gilead, BARDA, Internal, COVID, HEK293, Patient, Enactment, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Aspergillus, LNC, Organic acid, Hand, Candidiasis, Genentech, Coccidioidomycosis, Medicine, Asos, Development, RNA transfection, Sirna Therapeutics, Toxicity, Fine chemical, Pharmaceutical industry, Matina Brothers

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.

Matinas BioPharma Announces Chairman Succession Plan

Retrieved on: 
Wednesday, September 21, 2022
Transfer, National, Risk, Sanofi, LNC, Icahn School of Medicine at Mount Sinai, Director, NYSE, Hoffmann-La Roche, MD, Organic acid, RNA transfection, Sale, Emory University, Audit committee, Pakistan Institute of Public Finance Accountants, Company, Consultant, Private Securities Litigation Reform Act, Nomination, Partnership, Industry, Forbes, Forward-looking statement, Technology, MBA, BS, Vaccine, Psychology, Shenzhen International BT Leadership Summit, Solution, Amikacin, Greenwich, NYU, BioNTech, Fourth Estate Public Benefit Corp. v. Wall-Street.com, Board, Merrill (company), Gilead Sciences, Research, DNA, GLOBE, SEC, Form 10-K, Management, Fine chemical, Herb, Matina Brothers, Genentech, Biology

Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company.

Key Points: 
  • Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company.
  • This change is representative of the progress we have made as a Company, commented Herbert J. Conrad, Chairman of Matinas .
  • I am honored to be appointed as the next Chairman of the Board at Matinas, stated Eric J. Ende .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.

Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference

Retrieved on: 
Tuesday, May 3, 2022
Form 10-K, Cystic fibrosis, Mycosis, Forward-looking statement, EPA, DPA, Private Securities Litigation Reform Act, Company, Degenerative disease, Patient, LNC, Partnership, Infection, Cryptococcosis, Clinical trial, Enactment, NTM, BioNTech, Matina Brothers, Risk, DNA, Cystic Fibrosis Foundation, Vaccine, Organic acid, Sale, SEC, Solution, RNA transfection, Technology, Research, Consultant, DSMB, Pharmaceutical industry

A replay of the Matinas BioPharma presentation will be available on-demand to registered attendees for one month following the conference.

Key Points: 
  • A replay of the Matinas BioPharma presentation will be available on-demand to registered attendees for one month following the conference.
  • Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.